Analyst consensus
As at 9 November 2022
FY22
|
|
Low |
High |
Average (Mean) |
|
Revenue (£m) |
1,141.9 |
1,195.0 |
1,178.4 |
|
EBITDA (£m) |
202.1 |
216.3 |
208.5 |
|
EBIT (£m) |
100.9 |
114.8 |
107.3 |
|
PBT (£m) |
8.0 |
27.1 |
16.7 |
|
Net income (£m) |
6.9 |
21.4 |
13.5 |
|
Adjusted EPS (p) |
1.7 |
5.3 |
3.3 |
|
Net bank debt (£m) |
(261.1) |
(193.8) |
(231.6) |
|
Net debt (including lease liabilities) (£m) |
(1,079.6) |
(1,036.6) |
(1,060.8) |
FY23
|
|
Low |
High |
Average (Mean) |
|
Revenue (£m) |
1,184.1 |
1,291.0 |
1,248.0 |
|
EBITDA (£m) |
228.9 |
246.2 |
236.3 |
|
EBIT (£m) |
126.5 |
143.4 |
133.7 |
|
PBT (£m) |
35.8 |
53.3 |
44.5 |
|
Net income (£m) |
25.3 |
40.8 |
33.3 |
|
Adjusted EPS (p) |
6.3 |
9.8 |
8.1 |
|
Net bank debt (£m) |
(241.0) |
(162.4) |
(213.2) |
|
Net debt (including lease liabilities) (£m) |
(1,056.9) |
(1,005.2) |
(1,034.5) |
The figures shown above are on an adjusted, post IFRS 16 basis. They include estimates from five analysts at the following institutions who have updated their estimates in line with Company guidance following Spire Healthcare’s H1 22 results: Numis, Barclays, Berenberg, Jefferies and Peel Hunt.
